斑秃的局部免疫疗法：一项大型回顾性研究。
Topical Immunotherapy of Alopecia Areata: A Large Retrospective Study.
作者信息
Zerbinati Nicola, Esposito Cristina, D'Este Edoardo, Calligaro Alberto, Valsecchi Rossano
机构信息
Department of Surgical and Morphological Sciences, University of Insubria (Varese), Varese, Italy.
Dermatology Department of Centro Medico Polispecialistico, Pavia, Italy.
出版信息
Dermatol Ther (Heidelb). 2018 Mar;8(1):101-110. doi: 10.1007/s13555-018-0226-5. Epub 2018 Feb 13.
INTRODUCTION
Topical immunotherapy is frequently used in the treatment of alopecia areata (AA) although few studies report long-term follow-up. Our goals were to determine the efficacy and the prognostic factors of topical immunotherapy in a large cohort of patients with AA treated in the departments of Dermatology and Venereology of Bergamo, Como and Pavia, from 1978 to January 2016.
METHODS
A total of 252 patients with AA were evaluated retrospectively.
RESULTS
All our patients developed an allergic reaction to a 2% solution of dinitrochlorobenzene (DNCB) or squaric acid dibutylester (SADBE) or diphenylcyclopropenone (DPCP). No patients discontinued therapy because of side effects. In total 112 patients (44.05%, p < 0.001) had a good response. Statistical analysis revealed that the main prognostic factors influencing the clinical results were the severity of hair loss at the beginning of therapy, the duration of AA, a history of atopy (particularly eczema), and the early development of sensitization to the three sensitizers.
CONCLUSION
Topical immunotherapy in patients with AA is quite effective, mostly well tolerated, and provides prolonged therapeutic benefits.
引言
局部免疫疗法常用于斑秃（AA）的治疗，不过很少有研究报道长期随访情况。我们的目标是确定1978年至2016年1月在贝加莫、科莫和帕维亚的皮肤科与性病科接受治疗的一大群斑秃患者中局部免疫疗法的疗效及预后因素。
方法
对总共252例斑秃患者进行回顾性评估。
结果
我们所有患者均对2%二硝基氯苯（DNCB）溶液、二丁基二甲基丙烯酸酯（SADBE）或二苯基环丙烯酮（DPCP）发生了过敏反应。没有患者因副作用而停止治疗。总共112例患者（44.05%，p < 0.001）有良好反应。统计分析显示，影响临床结果的主要预后因素是治疗开始时脱发的严重程度、斑秃的病程、特应性病史（尤其是湿疹）以及对三种致敏剂致敏的早期发生情况。
结论
斑秃患者的局部免疫疗法相当有效，大多耐受性良好，并能提供长期治疗益处。
Zotero 插件